We are live on ! Find out more
FNCH

Finch Therapeutics Group, Inc. Common Stock
FNCH

Delisted

FNCH was delisted on the 24th of May, 2024.

Back to rankings

18 hedge funds and large institutions have $1.37M invested in Finch Therapeutics Group, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6% more funds holding

Funds holding: 17 → 18 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

37% less capital invested

Capital invested by funds: $2.16M → $1.37M (-$789K)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
18
Holders Change
+1
Holders Change %
+5.88%
% of All Funds
0.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
1
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MP
MSD Partners
New York
+$36.9K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$23.5K
3
MFT
Moisand Fitzgerald Tamayo
Florida
+$22

Top Sellers

Rank Fund Capital Flow
1
AMC
Avenir Management Company
New York
-$70.6K
2
IC
Ikarian Capital
Texas
-$7.39K
3
UBS Group
UBS Group
Switzerland
-$3.9K
4
TRCT
Tower Research Capital (TRC)
New York
-$1.57K
5
Bank of America
Bank of America
North Carolina
-$60
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$349K – – –
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$301K – – –
AMC
3
Avenir Management Company
New York
$236K -$70.6K -9,795 -18%
LSAG
4
Lake Street Advisors Group
New Hampshire
$222K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$186K +$23.5K +3,263 +10%
IC
6
Ikarian Capital
Texas
$35.1K -$7.39K -1,025 -13%
MP
7
MSD Partners
New York
$26.5K +$36.9K +5,113 New
BL
8
Bleichroeder LP
New York
$5.03K – – –
AA
9
Ancora Advisors
Ohio
$2.76K – – –
TRCT
10
Tower Research Capital (TRC)
New York
$2.27K -$1.57K -218 -33%
BlackRock
11
BlackRock
New York
$1.77K – – –
Morgan Stanley
12
Morgan Stanley
New York
$637 – – –
SPIA
13
Steward Partners Investment Advisory
New York
$389 – – –
Wells Fargo
14
Wells Fargo
California
$31 – – –
MFT
15
Moisand Fitzgerald Tamayo
Florida
$16 +$22 +3 New
UBS Group
16
UBS Group
Switzerland
$10 -$3.9K -541 -100%
Bank of America
17
Bank of America
North Carolina
– -$60 -7 Closed

FNCH Hedge Fund Activity: Q3 2023 in Review

18 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q3 2023, worth a combined $1.37M — down 37% from $2.16M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new FNCH positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.

The largest buyer was MSD Partners, opening a new position worth an estimated $36.9K. The largest seller was Avenir Management Company, cutting an estimated $70.6K.

  • 18 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q3 2023, up from 17 in Q2 2023.
  • Funds reported $1.37M of Finch Therapeutics Group, Inc. Common Stock stock for Q3 2023, down 37% quarter-over-quarter.
  • 2 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q3 2023 and 1 closed out, a net change of +1 holder.
  • The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q3 2023 was MSD Partners, an estimated $36.9K added.
  • The largest Finch Therapeutics Group, Inc. Common Stock seller in Q3 2023 was Avenir Management Company, an estimated $70.6K sold.

Based on aggregated 13F filings for Q3 2023.